AUPP823999A0 - A treatment - Google Patents

A treatment

Info

Publication number
AUPP823999A0
AUPP823999A0 AUPP8239A AUPP823999A AUPP823999A0 AU PP823999 A0 AUPP823999 A0 AU PP823999A0 AU PP8239 A AUPP8239 A AU PP8239A AU PP823999 A AUPP823999 A AU PP823999A AU PP823999 A0 AUPP823999 A0 AU PP823999A0
Authority
AU
Australia
Prior art keywords
chaperonin
ifn
beta
treatment
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP8239A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Priority to AUPP8239A priority Critical patent/AUPP823999A0/en
Publication of AUPP823999A0 publication Critical patent/AUPP823999A0/en
Priority to PCT/AU2000/000032 priority patent/WO2000043033A1/en
Priority to DK00903434T priority patent/DK1150703T3/da
Priority to KR1020017009163A priority patent/KR100694011B1/ko
Priority to CA2361081A priority patent/CA2361081C/en
Priority to AT00903434T priority patent/ATE313332T1/de
Priority to AU25271/00A priority patent/AU771867B2/en
Priority to PT00903434T priority patent/PT1150703E/pt
Priority to ES00903434T priority patent/ES2255484T3/es
Priority to DE60024967T priority patent/DE60024967T2/de
Priority to EP00903434A priority patent/EP1150703B1/en
Priority to JP2000594486A priority patent/JP4691257B2/ja
Priority to US12/362,456 priority patent/US20090214473A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Surgical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AUPP8239A 1999-01-20 1999-01-20 A treatment Abandoned AUPP823999A0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AUPP8239A AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment
JP2000594486A JP4691257B2 (ja) 1999-01-20 2000-01-20 シャペロニン１０及びβ−インターフェロンによる多発性硬化症の治療方法
AU25271/00A AU771867B2 (en) 1999-01-20 2000-01-20 Chaperonin 10 and beta-interferon therapy of multiple sclerosis
DK00903434T DK1150703T3 (da) 1999-01-20 2000-01-20 Behandling af multipel sclerose med chaperonin 10 og beta-interferon
KR1020017009163A KR100694011B1 (ko) 1999-01-20 2000-01-20 다발성 경화증의 샤페로닌 10 및 베타-인터페론 치료법
CA2361081A CA2361081C (en) 1999-01-20 2000-01-20 Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
AT00903434T ATE313332T1 (de) 1999-01-20 2000-01-20 Chaperonin 10 und beta-interferon therapie für multiple sklerose
PCT/AU2000/000032 WO2000043033A1 (en) 1999-01-20 2000-01-20 CHAPERONIN 10 AND β-INTERFERON THERAPY OF MULTIPLE SCLEROSIS
PT00903434T PT1150703E (pt) 1999-01-20 2000-01-20 Terapia de esclerose multipla com chaperonina 10 e beta-interferao
ES00903434T ES2255484T3 (es) 1999-01-20 2000-01-20 Terapia con chaperonina 10 y beta-interferon para la esclesosis multiple.
DE60024967T DE60024967T2 (de) 1999-01-20 2000-01-20 Chaperonin 10 und beta-interferon therapie für multiple sklerose
EP00903434A EP1150703B1 (en) 1999-01-20 2000-01-20 Chaperonin 10 and beta-interferon therapy of multiple sclerosis
US12/362,456 US20090214473A1 (en) 1999-01-20 2009-01-29 Combination chaperonin 10 and beta-interferon therapy for multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP8239A AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment

Publications (1)

Publication Number Publication Date
AUPP823999A0 true AUPP823999A0 (en) 1999-02-11

Family

ID=3812443

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPP8239A Abandoned AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment
AU25271/00A Ceased AU771867B2 (en) 1999-01-20 2000-01-20 Chaperonin 10 and beta-interferon therapy of multiple sclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU25271/00A Ceased AU771867B2 (en) 1999-01-20 2000-01-20 Chaperonin 10 and beta-interferon therapy of multiple sclerosis

Country Status (12)

Country Link
US (1) US20090214473A1 (https=)
EP (1) EP1150703B1 (https=)
JP (1) JP4691257B2 (https=)
KR (1) KR100694011B1 (https=)
AT (1) ATE313332T1 (https=)
AU (2) AUPP823999A0 (https=)
CA (1) CA2361081C (https=)
DE (1) DE60024967T2 (https=)
DK (1) DK1150703T3 (https=)
ES (1) ES2255484T3 (https=)
PT (1) PT1150703E (https=)
WO (1) WO2000043033A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548985A (en) * 2004-01-16 2010-02-26 Cbio Ltd Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
EP2457930A1 (en) 2005-08-31 2012-05-30 CBIO Limited Modified chaperonin 10
CN101330922A (zh) * 2005-10-20 2008-12-24 悉生物有限公司 超敏的治疗
CA2644058C (en) * 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015339A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Antagonists to chaperonin 10
JPH10500109A (ja) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療方法
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose

Also Published As

Publication number Publication date
KR20020002376A (ko) 2002-01-09
ATE313332T1 (de) 2006-01-15
AU2527100A (en) 2000-08-07
ES2255484T3 (es) 2006-07-01
CA2361081C (en) 2010-09-21
JP4691257B2 (ja) 2011-06-01
EP1150703B1 (en) 2005-12-21
EP1150703A1 (en) 2001-11-07
JP2002535286A (ja) 2002-10-22
KR100694011B1 (ko) 2007-03-12
CA2361081A1 (en) 2000-07-27
DE60024967D1 (en) 2006-01-26
PT1150703E (pt) 2006-05-31
WO2000043033A1 (en) 2000-07-27
DK1150703T3 (da) 2006-05-29
EP1150703A4 (en) 2004-11-10
DE60024967T2 (de) 2006-08-17
US20090214473A1 (en) 2009-08-27
AU771867B2 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AU3632497A (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
AU7031500A (en) Therapeutic quinazoline compounds
UA48946C2 (uk) Арилалкілдіазинони, спосіб їх одержання (варіанти), фармацевтичний склад, спосіб його одержання та спосіб лікування
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
AU5906398A (en) Dosage composition for nasal delivery and method of use of the same
AU6529796A (en) Biological agent compositions
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
AU4170197A (en) Pharmaceutical compounds
GR3006815T3 (https=)
EP1105407A4 (en) AMINOSTEROL DERIVATIVES AND THEIR USE
AUPP823999A0 (en) A treatment
GB9907571D0 (en) Compounds
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
EP0744176A3 (en) Methods for inhibiting bone loss
AU8851298A (en) L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof
WO2002046225A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
CA2293808A1 (en) Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 2527100

Country of ref document: AU